|Bid||40.00 x 100|
|Ask||59.95 x 100|
|Day's range||46.57 - 48.36|
|52-week range||41.67 - 91.35|
|PE ratio (TTM)||N/A|
|Earnings date||2 May 2018 - 7 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||64.71|
Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) today announce that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. XLH is a rare, chronic progressive musculoskeletal disorder that affects children and adults.
On a per-share basis, the Novato, California-based company said it had a loss of $1.89. Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Camille L. Bedrosian, M.D. as Executive Vice President and Chief Medical Officer. In this role, Dr. Bedrosian will provide strategic leadership to the clinical development and translational research programs, and will oversee Medical Affairs, Global Clinical Development groups, Clinical Operations and Drug Safety/Pharmacovigilance.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 4,385,965 shares of its common stock at a price to the public of $57.00 per share, resulting in gross proceeds of $250 million before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 657,895 shares of the company's common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, BofA Merrill Lynch, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.
Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the appointment of John Hohneker, M.D., as president and chief executive officer, effective January 22. Dr. Hohneker joins Anokion from FORMA Therapeutics Inc., where he served as president of research and development. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology.
Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim safety and efficacy data from the first dose cohort of the Phase 1/2 study of DTX301, an adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. “We are encouraged by these initial data showing activity with our AAV8 vector in patients in the first, lowest-dose cohort. Patient 1 showed a normalization of ureagenesis that was maintained through 12 weeks, and we view this initial efficacy data as clinically meaningful and a promising indication of the potential of DTX301,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced an update to its development plan for UX007 in patients with long-chain fatty acid oxidation disorder (LC-FAOD). Following an end-of-phase 2 meeting with the FDA, the company is working to provide additional information to submit to FDA for consideration of an early filing based on the results from the Phase 2 study. The company is simultaneously completing the design of a Phase 3 study that could be used for registrational or confirmatory purposes.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:30 am PT in San Francisco. The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Ultragenyx Pharmaceutical Inc. has agreed to sell a Food and Drug Administration-issued priority review voucher to Novartis AG for $130 million, the company said on Monday. Ultragenyx shares rose 3.4% ...
Ultragenyx popped to a seven-week high Monday on data from a Phase 3 trial for a drug to treat a rare bone disease.
Ultragenyx Pharmaceutical Inc. shares rose 4.4% in premarket trade Monday after the company said that the rare disease therapy it is developing with Kyowa Hakko Kirin Co. Ltd. had positive results in a ...
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
The Novato, California-based company said it had a loss of $1.87 per share. The results matched Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was also ...
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.